NVR RIC (Kisqali 200 mg)
Generic Name: ribociclib
Pill with imprint NVR RIC is Purple, Round and has been identified as Kisqali 200 mg. It is supplied by Novartis Pharmaceuticals Corporation.
Kisqali is used in the treatment of breast cancer, metastatic; breast cancer and belongs to the drug class CDK 4/6 inhibitors. Kisqali 200 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for NVR RIC
Kisqali
- Generic Name
- ribociclib
- Imprint
- NVR RIC
- Strength
- 200 mg
- Color
- Purple
- Size
- 11.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- CDK 4/6 inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Novartis Pharmaceuticals Corporation
- National Drug Code (NDC)
- 00078-0874
- Inactive Ingredients
-
silicon dioxide, crospovidone, magnesium stearate, microcrystalline cellulose, ferrosoferric oxide, ferric oxide red, soya lecithin, magnesium silicate, titanium dioxide, xanthan gum
Note: Inactive ingredients may vary.
Related Images for "NVR RIC"
More about Kisqali (ribociclib)
- Side Effects
- During Pregnancy
- Dosage Information
- Imprints, Shape & Color Data
- Drug Interactions
- En Español
- 4 Reviews
- Drug class: CDK 4/6 inhibitors
- FDA Alerts (1)
- FDA Approval History
Consumer resources
- Kisqali
- Kisqali (200 MG Dose)
- Kisqali (400 MG Dose)
- Kisqali (600 MG Dose)
- Kisqali (Advanced Reading)
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
